Breaking News

Althea, Profectus in Plasmid Production Pact

February 26, 2013

Althea to provide cGMP plasmid DNA for vaccine development

Althea Technologies and Profectus BioSciences have signed a manufacturing supply agreement for plasmid DNA production. Althea will provide gram-scale quantities of cGMP-manufactured plasmid DNA expressing IL-12 for Profectus Biosciences' ongoing DNA vaccine development efforts. IL-12 is designed to prompt an immune response once the DNA enters a cell, which is part of Profectus Biosciences' technology platform to overcome the poor delivery and immunogenicity of DNA vaccines.
"Profectus is very pleased to establish this partnership with Althea for the production of the clinical grade plasmids for our DNA vaccine programs," said John Eldridge, chief scientific officer of Profectus BioSciences. "Althea provides an unmatched combination of state-of-the-art facilities and expertise in this area and we anticipate a long and productive association."
"We are delighted to be awarded this contract, this project has tremendous potential for treating some of the world's most devastating and challenging diseases," said Rick Hancock, president and chief executive officer of Althea Technologies. "By establishing this partnership, Althea will be able to leverage our plasmid manufacturing expertise to help advance this DNA vaccines program through the clinic and to the patients who need it."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus